Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (76712)	12/28/1999 10:09:00 AM
From: Jenna	Read Replies (4) \| Respond to of 120523

<<TRIGGERs stocks # 12, #10 WL 12/28>> IONN closed position on IONN and am now short.. it was a good ride..

To: Jenna who wrote (76712)	12/28/1999 10:39:00 AM
From: kha vu	Respond to of 120523

IMMU: biz.yahoo.com <<<Immunomedics Develops New Fusion Protein with Improved Selectivity For Cancer Therapy MORRIS PLAINS, N.J., Dec. 28 /PRNewswire/ -- Immunomedics, Inc. (Nasdaq: IMMU - news) today announced that it has succeeded in making a genetically engineered bispecific antibody fusion protein for use in a two-step drug delivery for cancer therapy. The new bispecific fusion protein was made by linking portions of genes encoding two distinct antibodies, yielding a single protein molecule with two binding sites: one to the tumor and the other to a small molecule carrying a therapeutic agent. The fusion protein is half the size of a typical antibody, and is substantially humanized by molecular engineering. In a presentation made recently at the Antibody Engineering Conference in San Diego, CA, Company scientists reported that the bispecific antibody fusion protein showed excellent binding to human cancers grown in animals. In the first step of the method, the bispecific antibody fusion protein is injected intravenously and subsequently binds to cancer cells, while unbound material is cleared rapidly from the body. In a second step, a small drug carrier is injected and shows specific uptake into the tumors that have been bound by the fusion protein. As early as 4 hours after injection of the small molecule drug carrier, a 13-fold ratio of uptake of the therapeutic drug in the tumor, as compared to the blood, was measured, which is an 8-fold higher tumor selectivity ratio than achieved with directly antibody-bound drug. In experiments with chemically conjugated fusion proteins, drug targeting showed an almost 100-fold higher uptake in tumor than in normal tissues. The Company's Chairman and CEO, Dr. David M. Goldenberg, stated: ''This work is the result of an ongoing collaboration with IBC Pharmaceuticals, LLC, our affiliated company that was formed a year ago, and shows great promise for a powerful, highly-targeted, new cancer therapy.'' He added: ''Immunomedics is using the bispecific antibody fusion protein strategy as an enhanced delivery system for anticancer drugs, while IBC Pharmaceuticals is developing the same patented technology for superior targeting of therapeutic isotopes to cancer.'' Dr. Goldenberg further commented that: ''Immunomedics plans to test its first generation bispecific antibody fusion proteins in patients in about a year, while IBC Pharmaceuticals expects to begin clinical trials within the next few months.'' >>